ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SCLP Scancell Holdings Plc

10.05
0.25 (2.55%)
17 Jan 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Scancell Holdings Plc LSE:SCLP London Ordinary Share GB00B63D3314 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.25 2.55% 10.05 9.60 10.50 10.05 9.80 9.80 1,382,318 16:02:31
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -5.86M -0.0057 -17.63 101.6M
Scancell Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell was 9.80p. Over the last year, Scancell shares have traded in a share price range of 8.86p to 19.50p.

Scancell currently has 1,036,781,403 shares in issue. The market capitalisation of Scancell is £101.60 million. Scancell has a price to earnings ratio (PE ratio) of -17.63.

Scancell Share Discussion Threads

Showing 73026 to 73046 of 74525 messages
Chat Pages: Latest  2933  2932  2931  2930  2929  2928  2927  2926  2925  2924  2923  2922  Older
DateSubjectAuthorDiscuss
28/11/2024
08:37
"For repurposed drugs ‘Use’ patents may be filed to protect the ‘method of use’ of the drug for the new indication, however, use patents are typically weaker than composition-of-matter patents and are therefore more costly for the companies to enforce [99]. Use patents also do not prevent off-label prescriptions, in which medications are prescribed for indications or populations for which they have no regulatory approval for [102]. In the case of drug repurposing, this can mean prescription of the generic version of a drug instead of the more expensive patented alternative which has gone through the regulatory approval process for the new indication and achieved market exclusivity. To tackle this problem pharmaceutical companies are legally prohibited from advertising off-label indications, although physicians are able to prescribe its off-label uses, supported by evidence of their efficacy in it new indications [103] which may take away from potential profits."



As I said, the key is to make. The hospitals will then use it. The only status that prevents marketing AND use is Orphan drug for 6 years (the FDA does have a few other, but all of them provide protection from a few months and up to 3 years).

sci102
28/11/2024
08:25
That’s really good news.
rogerbridge
28/11/2024
07:58
'It’s quite common for multiple drugs to be prescribed together because they control different aspects of a condition, or they have a magnified effect when taken together—known as synergism—that is more than the sum of its parts. In either case, this provides an attractive opportunity for drug companies to create combinations of patented drugs and bring them to market as a newly patented product. A recent example of this is Symbyax—a combination of the drugs olanzapine (Zyprexa) and fluoxetine (Prozac)—that is indicated for the treatment of bipolar disorder.'
bermudashorts
28/11/2024
07:57
SCI what I mean apart from the Science is advanced is that SCLP has a much better balanced and experienced team to make progress re commercialisation of assets rather than simply trying to endlessly improve on the Science which I think they have been guilty of in the past
ivyspivey
28/11/2024
07:48
I am not mistaken Bermuda. I KNOW this space. Time (and the specific claims that are actually granted) will tell.
sci102
28/11/2024
07:45
Sci102

Sorry but you are mistaken re. the patent situation. New formulations and new combinatons are a standard way of extending patent life used by pharma for drugs nearing expiry of their patent. The SCIB1 combination patent hasn't been granted but the fact that it has been filed forms prior art and as you well know it can take years for drug patent applications to be granted.

bermudashorts
28/11/2024
07:45
Thanks - i didn't know there was any Prostrate trials or is this indicating it could potentially be used to address such cancers. Sorry my understanding is that great of the science.
plasybryn
28/11/2024
07:35
I do agree about the management but isn't it weird that the new CEO and the new CMO have not given an interview yet, or even a comment in the latest RNS?
sci102
28/11/2024
07:33
If it was a company the shares would have crashed........
A bit like your SCLP you mean ?

2tyke
28/11/2024
07:11
Nope. I warned a year ago about the hype of iscib1+. It was the company that was highlighting it wasn't it? Is the impression you got from latest communications that iscib1+ is the real focus, as they were strongly suggesting a year ago?
What does that say about the money that went into the development efforts (development in this space means IND work onwards), well spent?

If you think that SC is a better position now than it was a year ago then I really don't know what to tell you.

PS the pursuit of excellence does not involve hype and waste of resources. How come the "iscib1+ is the same or better" became "it needs to be a lot better", this is very far from excelence.

Lying to the people who supported you is not excellence in any shape or form. Bermuda is wrong about the additional patents of scib1(which by the way they have not even been granted yet), they are there to built upon previous IP which is expiring and they can't stand on their own. If it wasn't the case, iscib1+ would not need to be a lot better, the same would suffice.

sci102
28/11/2024
06:52
Morning SCi
That has often been one of criticisms by some on here that SCLP always wanting to go that bit further by fine tuning the Science.
This inevitable led to past delays and necessitated capital raises etc which has frustrated many LTH.
The more evangelical,here dismiss these issues as simply the pursuit of excellence in the Science.
Whilst in itself that is a laudable aim I would have preferred a more balanced commercial/ scientific pathway but no matter.
I do think we are in a much now better place as we have a proper management team to to progress things but only time will tell

ivyspivey
28/11/2024
05:24
Best move here is to keep scib1 for unresectable and refocus iscib1+ to resectable. Funds however remains an issue. They shouldn't have rushed iscib1+ development. Shouldhave wouldhave...
sci102
27/11/2024
21:54
per capita GDP

If it was a company the shares would have crashed, and the liquidators would be getting ready to take control. The National Audit Office has today refused to sign off on the UK’s accounts, citing a lack of information from local authorities on their potential liabilities. They can hardly be blamed for that. The grim truth is that the country’s balance sheet is a mess – and we may be a lot closer to bankruptcy than we realise.

The Chancellor Rachel Reeves may claim to have taken the “tough decisions” to put the national finances back on a “solid footing”. The trouble is, the people whose actual job it is to examine the books don’t see it the same way. The NAO today warned of “severe backlogs” in the audits of local authority finances which meant it did not have “sufficient, appropriate evidence” to sign off on the Whole Government Accounts, which combines the figures for more than 10,000 public bodies.

Translated from the restrained jargon of the accountancy profession, the message was simple. The numbers are about as reliable as Rachel Reeves’s CV, and we’re not putting our names to any books with more cooking than the final of Bake Off.

It is perfectly right to do so. In reality, local authorities have liabilities that are almost impossible to quantify right now. Eight councils have declared bankruptcy since 2020, typically as a result of bad investments as local finance offices try to trade their way out of the dire shortage of funds they face. No one really knows how many more might have made investments that are just as risky, or what kind of losses may eventually be racked up.

But the real problem is not just bad investments. They can always be ring-fenced or unwound. It is the soaring cost of a dysfunctional government machine. Local authorities face bills that are running away from them. The idiotic “war on landlords” has driven up rents, vastly increasing the cost of housing people who have nowhere to live. The price of social care for the elderly is rising all the time, and the increase in National Insurance will drive up the costs of homes that will be passed onto councils.

There are an increasing number of illegal asylum seekers – sorry, “irregular migrants” – that have to be looked after. And the courts are imposing backdated equal pay legislation that may land authorities with bills running into tens or hundreds of millions. Add all that up, and it is a surprise that more are not bankrupt already.

The central government is hardly in any better shape. The cost of gold-plated public sector pensions is going up all the time, with estimated liabilities of £1.3 trillion, although the true cost may turn out to be far higher. The outstanding stock of student loans is estimated to come to another £225 billion, and may be virtually worthless as no one has any real idea what percentage of them will ever be repaid.

Six or seven universities may soon go bust, again hit hard by the rise in NI, and will have to be bailed out at huge cost, or else wound down in an orderly manner, which unfortunately won’t be much cheaper. Net zero is turning into a huge drain on resources, with the endless virtual-signalling pledges on climate change racking up liabilities that no one had bothered to property tally up. The list goes on and on.

Asked how he went broke, an Ernest Hemingway character explains. “Gradually. And then suddenly.” The harsh reality is that the UK has been gradually running out of money for the last twenty years. We don’t know precisely how close to running out of money we are. But the NAO decision is a sign that the endgame may well be a lot closer than anyone realises right now. And the “graduallyR21; could turn to “suddenly̶1; any day now.

Telegraph

inanaco
27/11/2024
18:09
Well its on Starmers CV now ....
inanaco
27/11/2024
17:44
""The once world-leading United Kingdom now has a per capita income lower than even the poorest state in the United States."Per capita is GDP divided by population. In other words it's an average which can be one of the most misleading figures in statistics. It may be a poor indicator of prosperity as it doesn't take into account income inequality.
ruckrover
27/11/2024
16:45
And best not to embrace the inanaco mis-conception that good clinical progress equates to share price enhancement.
It hasn't....it usually doesn't...and it
probably won't.

2tyke
27/11/2024
16:37
well that's what the yanks think ....

“The once world-leading United Kingdom now has a per capita income lower than even the poorest state in the United States.”

inanaco
27/11/2024
16:36
Donald Trump’s pick for US energy secretary has previously attacked Britain’s net zero drive for making the country poorer.

In a report on sustainability released earlier this year, Chris Wright – who is being proposed for the job by the Trump transition team – said the UK’s embrace of green energy had been a costly failure that drove away investment.

Mr Wright suggested that the scramble to ditch fossil fuels in favour of wind and solar power had resulted in higher prices, driving away energy-intensive businesses and contributing to Britain’s national decline.


A report by his company, Liberty Energy, released in February, said: “The UK, although no longer part of the EU, has continued aggressive climate policies that have driven up energy prices for its citizens and industry. The results are troubling.

“The once world-leading United Kingdom now has a per capita income lower than even the poorest state in the United States.”

The comments highlight a gulf between the UK and the US around energy policy and climate change. Mr Trump is expected to embrace fracking and seek to dismantle legislation pushing the US towards net zero.

telegraph
----------------------------------------------------------------------------------

inanaco
27/11/2024
16:32
Well no Roger, not usually....just look at poor old inanaco... 😂
2tyke
27/11/2024
16:11
December approaches, let’s hope for a good deal.
Good things come to those who wait.

rogerbridge
27/11/2024
16:09
Glycans for Car T



(CAR) T-Cells that target the abnormal cell surface glycans

27mins

marcusl2
Chat Pages: Latest  2933  2932  2931  2930  2929  2928  2927  2926  2925  2924  2923  2922  Older

Your Recent History

Delayed Upgrade Clock